STAT

OCTOBER 11, 2024

Last week, the Food and Drug Administration declared an end to the shortage of Eli Lilly’s tirzepatide, sold under the brand name Mounjaro for diabetes and Zepbound for obesity.

Compounding 359

Compounding Diabetes 359

STAT

OCTOBER 8, 2024

A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list. Continue to STAT+ to read the full story…

Compounding 347

Compounding Compounding Pharmacies Diabetes Drug Pricing 347

STAT

SEPTEMBER 20, 2023

As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. for selling unapproved versions of its Mounjaro diabetes drug, which is frequently used for combating obesity.

Compounding 354

Compounding Compounding Pharmacies Diabetes 354

STAT

DECEMBER 20, 2024

The agency will give compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients. That should have prohibited compounders from continuing to make copies, because they can do so only when a treatment is on the shortage list.

Compounding 251

Compounding Diabetes 251

STAT

OCTOBER 23, 2024

Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. Novo has repeatedly argued that compounded products are risky, stressing that they are not approved by the FDA.

Compounding 255

Compounding Compounding Pharmacies Biosimilars Documentation 255

STAT

AUGUST 10, 2023

In late May, the Food and Drug Administration said it received a “few” adverse event reports concerning compounded versions of the injectable medicines, which both contain the same active ingredient, known as semaglutide. The notice raised an important question: To what extent should the public be concerned?

Compounding 246

Compounding Diabetes 246

STAT

OCTOBER 11, 2024

The Food and Drug Administration on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, from its shortage list, and, for the time being, would not pursue regulatory action against certain compounding pharmacies making copies of the drugs. 

Compounding Pharmacies 347

Compounding Pharmacies Compounding Diabetes 347

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. The agency then made a sudden about-face , saying it would reconsider its decision and allow compounders to continue for the meantime.

Compounding Pharmacies 355

Compounding Pharmacies Compounding Diabetes 355

STAT

DECEMBER 4, 2024

It mirrors results seen in the companies’ diabetes drugs, which use the same active ingredients.   A trade group for compounding pharmacies slammed an attempt by Novo Nordisk to convince the U.S. That, in turn, could help the company gain market share against Novo.  Continue to STAT+ to read the full story…

Compounding 184

Compounding Compounding Pharmacies Diabetes Documentation 184

STAT

SEPTEMBER 20, 2023

… As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. for selling unapproved versions of its Mounjaro diabetes drug, which is frequently used for combating obesity, STAT writes.

Compounding 248

Compounding Compounding Pharmacies Diabetes 248

STAT

FEBRUARY 26, 2024

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Diabetes 360

Diabetes Compounding Drug Development 360

STAT

AUGUST 2, 2024

In the face of ongoing shortages of the obesity and diabetes medications known as GLP-1s, patients have resorted to a wide array of sources for the drugs, including medical spas and telehealth sites that prescribe compounded versions of the drugs.

Online Pharmacies 359

Online Pharmacies Labelling Compounding Diabetes 359

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. The agency then made a sudden about-face , saying it would reconsider its decision and allow compounders to continue for the meantime.

Compounding Pharmacies 279

Compounding Pharmacies Compounding Diabetes 279

BioPharma Dive

DECEMBER 2, 2024

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.

Compounding 120

Compounding Compounding Pharmacies Diabetes 120

STAT

OCTOBER 17, 2024

Dozens of companies have started to offer the wildly popular obesity and diabetes medications, meeting patients who are flooding online for prescriptions that could help them lose as much as 20% of their body weight.  In the last two years, telehealth has gone all in on GLP-1s.

Compounding 361

Compounding Diabetes 361

Pharmaceutical Technology

MAY 7, 2025

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and diabetes drugs.

Compounding 59

Compounding Diabetes 59

Compounding Pharmacy of America

DECEMBER 6, 2024

While many men experience occasional difficulties with sexual performance, persistent ED can be an early warning sign of serious underlying health issues such as cardiovascular disease, diabetes, or hormonal imbalances.

Compounding Pharmacies 98

Compounding Pharmacies Compounding Diabetes 98

Express Pharma

NOVEMBER 4, 2024

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk’s diabetes drug, liraglutide, to its platform in 2025. Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication kits at $79 per month. regulations.

Compounding 106

Compounding Diabetes 106

pharmaphorum

OCTOBER 14, 2024

Faced with lawsuit, FDA rethinks block on compounding pharmacies making Eli Lilly's diabetes and obesity drug tirzepatide

Compounding 110

Compounding Compounding Pharmacies Diabetes 110

STAT

OCTOBER 31, 2024

… All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available  on the U.S. With all doses now listed as available, the FDA may soon pull it off the list, depending on its conversations with Novo about whether the company can sufficiently meet demand going forward.

Compounding Pharmacies 263

Compounding Pharmacies Compounding Diabetes Packaging 263

pharmaphorum

OCTOBER 23, 2024

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by these manufacturers.

Compounding 116

Compounding Compounding Pharmacies Diabetes 116

Express Pharma

MARCH 13, 2025

A recent study published in Springer Medizin has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a significant biomarker for disease progression in individuals at risk of type 1 diabetes (T1D). per cent, increasing from $2.2 billion in 2023 to $9.9 per cent, increasing from $2.2 billion in 2023 to $9.9

Diabetes 66

Diabetes Compounding 66

Express Pharma

JULY 28, 2024

Food and Drug Administration recently warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk’s weight-loss and diabetes drugs. The post US FDA flags dosing risks from compounded versions of Novo’s weight-loss drug appeared first on Express Pharma.

Compounding 103

Compounding Diabetes 103

PharmaVoice

OCTOBER 21, 2024

After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.

Compounding 174

Compounding Diabetes 174

STAT

JUNE 20, 2024

We have adjusted our settings to accept postcards and telegrams… After taking legal action last year, Eli Lilly filed even more lawsuits against several spas, compounders and wellness centers over unapproved versions of tirzepatide, which is the active ingredient in Mounjaro and Zepbound,   STAT notes.

Diabetes 280

Diabetes Compounding Drug Pricing Drug Development 280

STAT

JUNE 20, 2023

are illegally selling compounded versions of its medicines. All three drugs are used to treat diabetes, although Wegovy was also approved by U.S. In the latest fracas over obesity drugs , Novo Nordisk filed lawsuits alleging several medical spas, wellness clinics, and weight loss clinics around the U.S.

Compounding 246

Compounding Diabetes 246

STAT

SEPTEMBER 22, 2023

The techs who were queried identified chemotherapies; ADHD medicines; three drugs for weight loss and diabetes — Mounjaro, Ozempic, and Wegovy — and local anesthetics such as lidocaine as the top drugs experiencing shortages. And 72% said shortages very significantly or significantly impact their workflow.

Department of Veterans Affairs 269

Department of Veterans Affairs Pharmacy Technician Compounding Pharmacies Compounding 269

Compounding Pharmacy of America

FEBRUARY 23, 2023

Many people need to address diabetes. So, how well does compounding diabetic medication address symptoms and one’s lifestyle? The post Supplements and Compounding Diabetic Medications appeared first on The Compounding Pharmacy of America.

Compounding 52

Compounding Diabetes Compounding Pharmacies 52

STAT

JANUARY 25, 2024

last year after taking suspected fake versions of Novo Nordisk’s diabetes drug Ozempic , Reuters reports, citing data from America’s Poison Centers. One Ozempic and similar diabetes medicines have been increasingly used off label for weight loss. Food and Drug Administration to identify public health risks.

Labelling 253

Labelling Diabetes Compounding 253

STAT

MARCH 12, 2025

The agreement covering Zealand’s compound petrelintide, signals renewed efforts by Roche to catch up with obesity market leaders Novo Nordisk and Eli Lilly. billion in upfront cash , STAT writes.

Compounding 162

Compounding Diabetes 162

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. By law, that should have prohibited compounding pharmacies from making copies of the drug, as they are allowed to do so only when the treatment is on the shortage list.

Compounding 212

Compounding Compounding Pharmacies Diabetes Drug Development 212

Express Pharma

AUGUST 28, 2023

Queen’s University Belfast has designed a new 3D printed bandage which presents an innovative method of treatment to heal diabetic foot ulcers (DFUs). These scaffolds can release both a bulk and sustained release of antibiotic loaded molecules to treat diabetic ulcers.

Diabetes 98

Diabetes Dosage Compounding Hospitals 98

Safe Biologics

MARCH 5, 2025

On February 22nd, the US Food and Drug Administration (FDA) announced the resulution of a years-long shortage of semaglutide, the key ingredient in popular GLP-1 weight loss and diabetes medications Ozempic amd Wegovy. drug manufacturers would be on the low end for risk and pharmacy compounders would be on the high end.

Compounding Pharmacies 130

Compounding Pharmacies Compounding Diabetes 130

Pharmafile

JANUARY 20, 2023

Pharmaceutical company Merck has announced that it is attempting to reduce levels of a cancer-causing compound which has been found in its popular type 2 diabetes drugs. The compound, known as nitrosamines or NTTP, often emerges from chemical reactions that can take place throughout the manufacturing process. read more

Compounding 52

Compounding Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

Compounding Pharmacy of America

MARCH 29, 2024

An exploration of how proper diet, exercise, and a regiment of supplements combined with GLP-1 therapies can prevent and treat type 2 diabetes. The post The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment appeared first on The Compounding Pharmacy of America.

Diabetes 59

Diabetes Compounding Pharmacies Compounding 59

Pharmaceutical Technology

MARCH 26, 2024

for novel compounds targeting apelin receptors. Learn about the compound's potential in treating cardiovascular disease, diabetes, cancer, and more. Discover the groundbreaking patent by Sosei Group Corp.

Compounding 52

Compounding Diabetes 52

Express Pharma

JANUARY 14, 2025

Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.3 billion in 2023 and is expected to grow at a CAGR of 8.4 per cent from 2024 to 2030.

Diabetes 105

Diabetes Compounding 105